Effect of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy on Quality of Life in Patients with Peritoneal Mesothelioma
- 207 Downloads
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) is an accepted treatment for peritoneal mesothelioma. In this study, we evaluated QOL after HIPEC for peritoneal mesothelioma.
This was a prospective study performed after HIPEC for peritoneal mesothelioma between 2002 and 2015. Patients completed QOL surveys, including the Short Form-36 (SF-36), Functional Assessment of Cancer Therapy + Colon (FACT-C), Brief Pain Inventory (BPI), and Center for Epidemiologic Studies Depression Scale (CES-D) preoperatively and at 3, 6, 12, and 24 months postoperatively.
Overall, 46 patients underwent HIPEC for peritoneal mesothelioma and completed QOL surveys. Mean age was 52.8 ± 13.8 years and 52% were male. Good preoperative functional status was 70%. Median survival was 3.4 years, and 1, 3, and 5-year survivals were 77.4, 55.2, and 36.5%, respectively. CES-D score decreased at 3 months postoperatively, but increased at 24 months (p = 0.014); SF-36 physical functioning scale decreased at 3 months but returned to baseline at 12 months (p = 0.0045); and the general health scale decreased at 3 months, then improved by 6 months (p = 0.0034). Emotional well-being (p = 0.0051), role limitations due to emotional problems (p = 0.0006), social functioning (p = 0.0022), BPI (p = 0.025), least pain (p = 0.045), and worst pain (p < 0.0001) improved. FACT-C physical well-being decreased at 3 months but returned to baseline at 6 months (p = 0.020), and total FACT-C score improved at 6 months (p = 0.052).
QOL returned to baseline or improved from baseline between 3 months and 1 year following surgery. Despite the risks associated with this operation, patients may tolerate HIPEC well and have good overall QOL postoperatively.
Supported in part by the Orin Smith Family fund.
- 7.Dodson RM, et al. Quality-of-life evaluation after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2016;23 Suppl 5:72–783.Google Scholar
- 10.Votanopoulos KI, Sugarbaker P, Deraco M, Morris D, Glehen O, Elias D, et al.; RENAPE Working Group. Is Cytoreductive surgery with heated intraperitoneal chemotherapy justified for biphasic variants of peritoneal mesothelioma? Outcomes from Peritoneal Surface Oncology Group International Registry. Ann Surg Oncol. 2018;25(3):667–73.Google Scholar
- 21.Blackham A, Levine EA. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma. Eur J Clin Med Oncol. 2012;4:25–32.Google Scholar
- 23.Ihemelandu CU, McQuellon R, Shen P, Stewart JH, Votanopolos KI, Levine EA. Predicting Postoperative Morbidity following Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (CS + HIPEC) with preoperative FACT-C (Functional Assessment of Cancer Therapy) and Patient Rated Performance Status. Ann Surg Oncol. 2013;20;3519–3526.CrossRefGoogle Scholar
- 25.Busija L, Pausenberger E, Haines TP, Haymes S, Buchbinder R, Osborne RH. Adult measures of general health and health‐related quality of life: Medical Outcomes Study Short Form 36‐Item (SF‐36) and Short Form 12‐Item (SF‐12) Health Surveys, Nottingham Health Profile (NHP), Sickness Impact Profile (SIP), Medical Outcomes Study Short Form 6D (SF‐6D), Health Utilities Index Mark 3 (HUI3), Quality of Well‐Being Scale (QWB), and Assessment of Quality of Life (AQOL). Arthritis Care & Research, 2011; 63: S383–S412.CrossRefGoogle Scholar
- 26.Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative. J Clin Oncol. 2001;19(4):1001–7.CrossRefGoogle Scholar